<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03936153</url>
  </required_header>
  <id_info>
    <org_study_id>XYN-606</org_study_id>
    <nct_id>NCT03936153</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)</brief_title>
  <official_title>An Open-label, Single-arm, Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Abexinostat as Monotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xynomic Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xynomic Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of
      abexinostat, as monotherapy in patients with relapsed or refractory diffuse large B-cell
      lymphoma (DLBCL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, single-arm, multi-center phase 2 study to evaluate the efficacy and safety of
      oral histone deacetylase (HDAC)-inhibitor abexinostat, as monotherapy in patients with
      relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A single arm treatment group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical effect by evaluating the objective response rate (ORR)</measure>
    <time_frame>up to 56 days</time_frame>
    <description>To evaluate the objective response rate (ORR) of abexinostat in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as assessed by an independent central imaging review.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response</measure>
    <time_frame>up to 56 days</time_frame>
    <description>Objective response rate (ORR) as assessed by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression-free survival (PFS), defined as the time from the initiation of treatment to disease progression or death as assessed by the independent Central Imaging Review and the Investigator.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <arm_group>
    <arm_group_label>Abexinostat 80 mg bis in die (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abexinostat 80 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abexinostat</intervention_name>
    <description>abexinostat tablet</description>
    <arm_group_label>Abexinostat 80 mg bis in die (BID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diffuse large B-cell lymphoma (DLBCL);

          2. Have received only two prior standard therapy lines for diffuse large B-cell lymphoma
             (DLBCL) including anti- cluster of differentiation antigen (anti-CD20) antibody and
             cytotoxic therapy;

          3. Confirmed to be unresponsive to the last line of therapy, or have disease progression
             following the last line of therapy;

          4. Have at least one radiologically measurable lymph node or extranodal lymphoid
             malignant lesion;

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2;

          6. Meet various hematological, liver and renal function lab parameters.

        Exclusion Criteria:

          1. Have primary central nervous system (CNS) lymphoma or secondary central nervous system
             (CNS) infiltration, transformed lymphoma, unclassified B-cell lymphoma with features
             intermediate between DLBCL and classical Hodgkin's lymphoma (HL), primary effusion
             lymphoma, plasma lymphoma;

          2. Toxicity not yet recovered from previous anti-tumor therapies;

          3. Uncontrolled systemic infections or infections requiring intravenous antibiotics;

          4. Have received steroid hormone, chemotherapy, targeted therapy, radiotherapy,
             antibody-based therapies, within a specified amount of time per protocol;

          5. Unable to swallow tablets, or presence of significant functional gastrointestinal
             disorders that may affect the intake, transport or absorption of the study drug;

          6. Have received autologous stem cell transplant,or allogeneic stem cell transplant
             within a certain amount of time as specified in protocol;

          7. Presence of active graft-versus-host reaction;

          8. Have undergone a major surgery within the last month;

          9. Evidence of possible human immunodeficiency virus (HIV) infection or hepatitis C virus
             (HCV) infection;

         10. Have any cardiac impairment as defined per protocol;

         11. Have prior history of malignancies other than diffuse large B-cell lymphoma (DLBCL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuankai SHI, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bing Zhao, MD</last_name>
    <phone>(01186)13716386801</phone>
    <email>bing.zhao@xynomicpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophia Paspal, PhD RAC</last_name>
    <phone>610-405-5974</phone>
    <email>sophia.paspal@xynomicpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuankai Shi, MD, PhD</last_name>
      <phone>13701251865</phone>
      <email>syuankaipumc@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenling Li, M.M.</last_name>
      <phone>13520114408</phone>
      <email>zryyxy2013@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fifth Medical Center of Chinese PLA General Hospital (Beijing 302 Hospital)</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hang Su, M.M.</last_name>
      <phone>13701396736</phone>
      <email>suhang307@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Ke, MD</last_name>
      <phone>13911068649</phone>
      <email>xiaoyank@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liqun Zou, MD</last_name>
      <phone>18980601027</phone>
      <email>zliqun@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliate Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <zip>116011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yajie Gao, M.M.</last_name>
      <phone>15541192088</phone>
      <email>gaoyajie100@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tingbo Liu, PhD</last_name>
      <phone>13365910316</phone>
      <email>13769988835@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Wu, M.M.</last_name>
      <phone>13509320201</phone>
      <email>kkwff123@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chuan Jin, M.M.</last_name>
      <phone>13688896983</phone>
      <email>jinchuan5959@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yai-Sen Memorial Hospital, Sun Yai-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yudan Wu, M.M.</last_name>
      <phone>13719472080</phone>
      <email>danwuxu@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyan Yang, MD</last_name>
      <phone>13857182590</phone>
      <email>haiyanyang1125@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Tumor Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang, MD</last_name>
      <phone>13313612989</phone>
      <email>sy86298276@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yaming Xi, MD</last_name>
      <phone>13919110815</phone>
      <email>xiyaming02@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <zip>276000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhen Wang, M.M.</last_name>
      <phone>15168920632</phone>
      <email>LYSZLYYNSK@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiao Tong University School Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunkang Chang, MD</last_name>
      <phone>13764643870</phone>
      <email>Changchunkang7010@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junning Cao, M.M.</last_name>
      <phone>13817384270</phone>
      <email>cao_junning@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second People's Hospital of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <zip>China</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Du, MD</last_name>
      <phone>13602523722</phone>
      <email>duxingz@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Forth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yuhuan Gao, MD</last_name>
      <phone>13503217908</phone>
      <email>ydsygao@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weihua Zhang, MD</last_name>
      <phone>13015474570</phone>
      <email>zwhlzh@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liling Zhang, MD</last_name>
      <phone>15871725926</phone>
      <email>lily1228@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <zip>221006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyu Li, MD</last_name>
      <phone>13852439312</phone>
      <email>frankfeng_2004@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yufu Li, MD</last_name>
      <phone>13598009218</phone>
      <email>liyufu439@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhi Zhang, MD</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abexinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

